Similarly, another two-cohort phase II trial of niraparib in pretreated patients with solid tumors (including mesothelioma) and BAP-1 or other DDR genes mutations failed to meet the pre-specified efficacy threshold of ORR (NCT03207347). The gene discussed is BAP1; the disease is mesothelioma.